Review Expert opinion on emerging drugs. 2025 May 29. doi: 10.1080/14728214.2025.2508994 Q22.72025

Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms

新兴的酪氨酸激酶抑制剂在神经内分泌肿瘤治疗中的应用翻译改进

Nicola Fazio¹, Anna La Salvia²

作者单位 +展开

作者单位

¹ Division of gastrointestinal medical oncology and neuroendocrine tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

² National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy.

DOI: 10.1080/14728214.2025.2508994 PMID: 40439196

摘要中英对照阅读

Introduction: In the era of precision medicine, a molecularly targeted therapeutical approach is still missing in the field of neuroendocrine neoplasms (NENs) other than for radioligand therapy (RLT). So far sunitinib is the only tyrosine kinase inhibitor (TKI) available in clinical practice for NENs in Western countries, limited to advanced, progressing pancreatic neuroendocrine tumors (NETs). A few TKIs worldwide reached an... ...点击完成人机验证后继续浏览

简介： 在精准医疗时代，除了放射配体治疗（RLT）外，神经内分泌肿瘤（NENs）领域仍缺乏分子靶向治疗方法。到目前为止，在西方国家用于治疗NEN的临床实践中，索坦是唯一可用的酪氨酸激酶抑制剂（TKI），仅限于进展期胰腺神经内分泌肿瘤（NET）。全球范围内有一些TKI已经进入临床试验的高级阶段，并取得了令人鼓舞的结果。

涵盖领域： 这篇叙述性综述是对NENs临床研究最高阶段所用TKIs现状的最新分析。我们的工作主要集中在对III期临床试验中调查的TKI（如Axitinib、Surufatinib和Cabozantinib）进行批判性分析。

专家观点： 我们手稿中的“专家意见”部分是对来自II期和III期临床试验中使用Axitinib、Surufatinib和Cabozantinib的结果的批判性概述，主要集中在这些TKI的研究策略上，包括地理区域以及研究设计方面的间接比较。

关键词： 新兴靶向药物；临床试验；神经内分泌肿瘤；酪氨酸激酶抑制剂。

翻译效果不满意？用Ai改进或寻求AI助手帮助，对摘要进行重点提炼

相关内容

期刊名：Expert opinion on emerging drugs

缩写：EXPERT OPIN EMERG DR

ISSN：1472-8214

e-ISSN：1744-7623

IF/分区：2.7/Q2

文章目录更多期刊信息

全文链接

官方链接

PMC全文

引文链接

复制

已复制！

格式：

Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms

新兴的酪氨酸激酶抑制剂在神经内分泌肿瘤治疗中的应用翻译改进

Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms

神经内分泌肿瘤的酪氨酸激酶抑制剂和免疫疗法最新进展

Zebrafish model in the relentless race to tyrosine kinase inhibitors for neuroendocrine neoplasms

神经内分泌肿瘤耐药机制及酪氨酸激酶抑制剂抗肿瘤作用的斑马鱼模型研究

Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review

神经内分泌肿瘤患者的酪氨酸激酶抑制剂的系统文献回顾

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors

克服对第一代表皮生长因子受体酪氨酸激酶抑制剂耐药性的分子机制

Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico

不可手术及转移性胃肠间质瘤的治疗：墨西哥三级医院使用酪氨酸激酶抑制剂的经验

Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors

酪氨酸激酶抑制剂治疗的EGFR突变转移性非小细胞肺癌患者的疗效预测因素

Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors

酪氨酸激酶抑制剂可降低尿激酶受体的表达水平

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

酪氨酸激酶抑制剂与甲状腺功能检测结果的改变：综述

Synthesis of novel 1,4-benzoxazin-3-one derivatives as inhibitors against tyrosine kinases

新型苯并噁嗪酮衍生物作为酪氨酸激酶抑制剂的研究

Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms

新兴的酪氨酸激酶抑制剂在神经内分泌肿瘤治疗中的应用 翻译改进

Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms

神经内分泌肿瘤的酪氨酸激酶抑制剂和免疫疗法最新进展

Zebrafish model in the relentless race to tyrosine kinase inhibitors for neuroendocrine neoplasms

神经内分泌肿瘤耐药机制及酪氨酸激酶抑制剂抗肿瘤作用的斑马鱼模型研究

Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review

神经内分泌肿瘤患者的酪氨酸激酶抑制剂的系统文献回顾

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors

克服对第一代表皮生长因子受体酪氨酸激酶抑制剂耐药性的分子机制

Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico

不可手术及转移性胃肠间质瘤的治疗：墨西哥三级医院使用酪氨酸激酶抑制剂的经验

Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors

酪氨酸激酶抑制剂治疗的EGFR突变转移性非小细胞肺癌患者的疗效预测因素

Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors

酪氨酸激酶抑制剂可降低尿激酶受体的表达水平

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

酪氨酸激酶抑制剂与甲状腺功能检测结果的改变：综述

Synthesis of novel 1,4-benzoxazin-3-one derivatives as inhibitors against tyrosine kinases

新型苯并噁嗪酮衍生物作为酪氨酸激酶抑制剂的研究

新兴的酪氨酸激酶抑制剂在神经内分泌肿瘤治疗中的应用翻译改进